DECOY THERAPEUTICS INC (DCOY) Stock Price & Overview
NASDAQ:DCOY • US79400X5032
Current stock price
The current stock price of DCOY is 5.8 USD. Today DCOY is down by -8.23%. In the past month the price decreased by -17.02%.
DCOY Key Statistics
- Market Cap
- 3.074M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -39.17
- Dividend Yield
- N/A
DCOY Stock Performance
DCOY Stock Chart
DCOY Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to DCOY.
DCOY Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to DCOY. DCOY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
DCOY Earnings
DCOY Forecast & Estimates
6 analysts have analysed DCOY and the average price target is 30.6 USD. This implies a price increase of 427.59% is expected in the next year compared to the current price of 5.8.
DCOY Groups
Sector & Classification
DCOY Financial Highlights
Over the last trailing twelve months DCOY reported a non-GAAP Earnings per Share(EPS) of -39.17. The EPS increased by 68.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.08% | ||
| ROE | -117.81% | ||
| Debt/Equity | 0 |
DCOY Ownership
DCOY Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 380.121B | ||
| AMGN | AMGEN INC | 15.24 | 190.443B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 174.171B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 113.617B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 82.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 43.596B | ||
| INSM | INSMED INC | N/A | 35.536B | ||
| NTRA | NATERA INC | N/A | 28.801B | ||
| BIIB | BIOGEN INC | 11.03 | 26.972B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.995B | ||
| MRNA | MODERNA INC | N/A | 19.759B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.548B | ||
| INCY | INCYTE CORP | 12.53 | 18.767B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DCOY
Company Profile
Decoy Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2015-01-29. Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
Company Info
IPO: 2015-01-29
DECOY THERAPEUTICS INC
2450 Holcombe Blvd Ste J-608
Houston TEXAS US
Employees: 2
Phone: 13026587581
DECOY THERAPEUTICS INC / DCOY FAQ
What does DCOY do?
Decoy Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2015-01-29. Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
What is the stock price of DECOY THERAPEUTICS INC today?
The current stock price of DCOY is 5.8 USD. The price decreased by -8.23% in the last trading session.
Does DCOY stock pay dividends?
DCOY does not pay a dividend.
What is the ChartMill technical and fundamental rating of DCOY stock?
DCOY has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of DECOY THERAPEUTICS INC (DCOY)?
DECOY THERAPEUTICS INC (DCOY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-39.17).